{
  "slug": "alzheimers",
  "title": {
    "zh": "阿茲海默症：亞洲管線與全球對手",
    "en": "Alzheimer’s disease: Asian pipelines and global competitors"
  },
  "answer": {
    "zh": "截至 2026-11-14，亞洲公司衛采的 lecanemab 已有核准產品，E2814 正進行第二期試驗；韓國 GemVax 的 GV1001 全球第二期試驗已完成。全球對手包括禮來的 donanemab，以及百健研究中的 tau 反義寡核苷酸 diranersen。本頁依機制與開發狀態比較，未將跨試驗結果排成療效名次。",
    "en": "As of 2026-11-14, Eisai has an approved lecanemab product and an active Phase 2 E2814 trial, while GemVax’s global Phase 2 GV1001 trial is completed. Global comparators include Lilly’s donanemab and Biogen’s investigational tau antisense therapy diranersen. The table separates mechanisms and development status without ranking efficacy across trials."
  },
  "scope": {
    "zh": "聚焦疾病修飾治療；核准適用地區及試驗族群分列，未收錄所有症狀控制藥。",
    "en": "Focus: disease-modifying therapies. Jurisdictions and trial populations are separated; symptomatic medicines are not exhaustively covered."
  },
  "as_of": "2026-11-14",
  "window_start": "2026-08-17",
  "window_end": "2026-11-14",
  "rows": [
    {
      "id": "alz-eisai-lecanemab",
      "company": {
        "zh": "衛采／百健",
        "en": "Eisai / Biogen"
      },
      "asset": "lecanemab / LEQEMBI",
      "asia": true,
      "mechanism": {
        "zh": "抗 Aβ 原纖維抗體",
        "en": "Anti-Aβ protofibril antibody"
      },
      "stage": {
        "zh": "已核准；日本含皮下注射筆",
        "en": "Approved; SC pen also approved in Japan"
      },
      "indication": {
        "zh": "早期阿茲海默症",
        "en": "Early Alzheimer’s disease"
      },
      "route": {
        "zh": "靜脈／皮下",
        "en": "IV / SC"
      },
      "latest": {
        "zh": "公告預定 11 月 CTAD 報告五年追蹤資料；會議尚未舉行。",
        "en": "Announced planned five-year follow-up presentations at November CTAD; the conference has not yet occurred."
      },
      "date": "2026-10-29",
      "sources": [
        {
          "url": "https://media-us.eisai.com/2026-10-29-Eisai-to-Present-New-Five-Year-Lecanemab-Data-and-Real-World-Alzheimers-Disease-Research-at-the-19th-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference",
          "title": "Eisai CTAD announcement",
          "date": "2026-10-29",
          "accessed_at": "2026-11-15"
        },
        {
          "url": "https://investors.biogen.com/node/31011",
          "title": "LEQEMBI Pen Japan approval",
          "date": "2026-09-16",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "alz-gemvax",
      "company": {
        "zh": "GemVax（韓國）",
        "en": "GemVax (South Korea)"
      },
      "asset": "GV1001",
      "asia": true,
      "mechanism": {
        "zh": "模擬 hTERT 額外端粒功能的研究中胜肽",
        "en": "Investigational peptide mimicking extra-telomeric hTERT functions"
      },
      "stage": {
        "zh": "全球第二期已完成；未核准",
        "en": "Global Phase 2 completed; not approved"
      },
      "indication": {
        "zh": "輕至中度阿茲海默症",
        "en": "Mild-to-moderate Alzheimer’s disease"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "NCT05189210 登錄為已完成；公司網頁仍寫進行中，本表採登錄狀態。",
        "en": "NCT05189210 is completed. The company webpage still says ongoing; this table uses the registry status."
      },
      "date": "2025-09-04",
      "sources": [
        {
          "url": "https://clinicaltrials.gov/study/NCT05189210",
          "title": "GV1001 global Phase 2 registry",
          "date": "2025-09-04",
          "accessed_at": "2026-11-15"
        },
        {
          "url": "https://www.gemvax.com/sub/expand_access.php",
          "title": "GemVax expanded access page",
          "date": null,
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "NCT05189210",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "alz-eisai-e2814",
      "company": {
        "zh": "衛采",
        "en": "Eisai"
      },
      "asset": "E2814",
      "asia": true,
      "mechanism": {
        "zh": "抗 tau 抗體，合併 lecanemab",
        "en": "Anti-tau antibody with lecanemab"
      },
      "stage": {
        "zh": "第二期；進行中、停止收案",
        "en": "Phase 2; active, not recruiting"
      },
      "indication": {
        "zh": "早期阿茲海默症",
        "en": "Early Alzheimer’s disease"
      },
      "route": {
        "zh": "靜脈；合併 lecanemab",
        "en": "IV; with lecanemab"
      },
      "latest": {
        "zh": "NCT06602258 登錄為進行中、停止收案；未公布確證性療效結論。",
        "en": "NCT06602258 is active, not recruiting; confirmatory efficacy has not been established."
      },
      "date": "2026-02-11",
      "sources": [
        {
          "url": "https://clinicaltrials.gov/study/NCT06602258",
          "title": "E2814 Phase 2 registry",
          "date": "2026-02-11",
          "accessed_at": "2026-11-15"
        },
        {
          "url": "https://eisaiclinicaltrials.com/wp-content/uploads/2025/12/EISAI_PLPS_E2814-G000-202_ENG.pdf",
          "title": "E2814 study protocol synopsis",
          "date": null,
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "NCT06602258",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "alz-lilly",
      "company": {
        "zh": "禮來",
        "en": "Eli Lilly"
      },
      "asset": "donanemab / Kisunla",
      "asia": false,
      "mechanism": {
        "zh": "抗類澱粉蛋白抗體",
        "en": "Anti-amyloid antibody"
      },
      "stage": {
        "zh": "已核准；適用範圍依地區",
        "en": "Approved; indications vary by jurisdiction"
      },
      "indication": {
        "zh": "早期症狀性阿茲海默症",
        "en": "Early symptomatic Alzheimer’s disease"
      },
      "route": {
        "zh": "靜脈",
        "en": "IV"
      },
      "latest": {
        "zh": "公告 AAIC 的診斷與治療研究議程；不代表新增適應症核准。",
        "en": "Announced diagnostic and therapeutic research at AAIC; this is not a new indication approval."
      },
      "date": "2026-07-09",
      "sources": [
        {
          "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-present-alzheimers-disease-diagnostic-and-therapeutic",
          "title": "Lilly AAIC research announcement",
          "date": "2026-07-09",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "alz-biogen",
      "company": {
        "zh": "百健／Ionis",
        "en": "Biogen / Ionis"
      },
      "asset": "diranersen / BIIB080",
      "asia": false,
      "mechanism": {
        "zh": "針對 MAPT mRNA 的反義寡核苷酸",
        "en": "Antisense oligonucleotide targeting MAPT mRNA"
      },
      "stage": {
        "zh": "第二期結果已公布；第三期為規畫",
        "en": "Phase 2 data reported; Phase 3 planned"
      },
      "indication": {
        "zh": "早期阿茲海默症",
        "en": "Early Alzheimer’s disease"
      },
      "route": {
        "zh": "鞘內",
        "en": "Intrathecal"
      },
      "latest": {
        "zh": "Ionis 第三季公告將 diranersen 第三期啟動列為 2027 年預期里程碑；仍屬預期。",
        "en": "Ionis lists Phase 3 initiation of diranersen as an anticipated 2027 milestone in its Q3 update; this remains forward-looking."
      },
      "date": "2026-11-09",
      "sources": [
        {
          "url": "https://ir.ionispharma.com/news-releases/news-release-details/ionis-reports-third-quarter-2026-financial-results-and",
          "title": "Ionis Q3 update: anticipated milestones",
          "date": "2026-11-09",
          "accessed_at": "2026-11-15"
        },
        {
          "url": "https://investors.biogen.com/node/30826",
          "title": "Biogen CELIA data",
          "date": "2026-07-14",
          "accessed_at": "2026-11-15"
        },
        {
          "url": "https://investors.biogen.com/static-files/e68b8af3-5678-4479-afa7-9f5113672e20",
          "title": "Biogen CELIA patient disposition and intrathecal dosing",
          "date": null,
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    }
  ]
}
